Drug intelligence / Profile preview

recombinant human thrombopoietin + thalidomide

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Oral

Overview

This is a combination therapy consisting of recombinant human thrombopoietin (rhTPO) and thalidomide. Recombinant human thrombopoietin is a biologic agent that mimics endogenous thrombopoietin, the primary regulator of platelet production, by stimulating megakaryocyte proliferation and differentiation to increase platelet counts. Thalidomide is an immunomodulatory small molecule with anti-angiogenic and anti-inflammatory properties; it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine release, and affects T-cell function. This combination has been explored for hematologic disorders where both stimulation of platelet production (via rhTPO) and immunomodulation/anti-angiogenesis (via thalidomide) may be beneficial.

Other names: recombinant human thrombopoietin and thalidomide

Targets

TPOR (Thrombopoietin receptor)CRBN (Cereblon)

Beyond the preview

Go deeper on recombinant human thrombopoietin + thalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human thrombopoietin + thalidomide.

Explore the full profile